Immunology and Biotherapies
12.3K views | +0 today
Follow
 
Scooped by Gilbert C FAURE
onto Immunology and Biotherapies
Scoop.it!

Lorvotuzumab mertansine, a CD56-targeting antibody-drug... [MAbs. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

The present status and future prospects of peptide-based cancer vaccines

The present status and future prospects of peptide-based cancer vaccines | Immunology and Biotherapies | Scoop.it
Abstract Tumor cells commonly express several antigens, such as tumor-associated antigens (TAAs) or mutation-derived antigens (neoantigens), that can be regarded as foreign antigens and elicit anti-tumor immune responses in cancer patients. Various TAAs or neoantigens expressed in cancer cells have been identified and utilized as targets for cancer vaccines. One approach to elicit tumor-specific immune responses is termed peptide-based cancer vaccination; it involves administrating TAAs or neoantigen-derived peptide for treatment of cancers. There have been several forms of peptide-based cancer vaccines depending on which effector cells, such as cytotoxic T lymphocytes (CTLs) or CD4+ T-helper cells, are targeted to be activated. Many phase I and II clinical trials of peptide-based cancer vaccines using TAA-derived CTL epitopes, T-helper cell epitopes, or dendritic cells loaded with TAA-derived peptides for various malignant tumors have been conducted and provide clinical benefits in a small fraction of patients. Nowadays, to improve the efficiency of peptide-based cancer vaccines, combination immunotherapy of peptide-based cancer vaccines with the immune-checkpoint blockade therapies using monoclonal antibodies (mAbs) specific for CTL antigen 4 (CTLA-4), programmed cell death 1 (PD-1), or PD-1 ligand 1 (PD-L1) have been developed for clinical application. Furthermore, along with the recent technological progress in genetic and bioinformatic analysis, it has become easier to identify neoantigens from individual cancer patients. It is expected that peptide-based cancer vaccines targeting neoantigens as a personalized cancer immunotherapy will be developed. © The Japanese Society for Immunology. 2016. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. KEYWORDS: neoantigen; peptide-based cancer vaccine; tumor-associated antigen; tumor-reactive T cell

Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 30, 7:32 AM
Int Immunol. 2016 May 28. pii: dxw027. [Epub ahead of print] The present status and future prospects of peptide-based cancer vaccines. Hirayama M1, Nishimura Y2.
Scooped by Gilbert C FAURE
Scoop.it!

First-in-class small molecule potentiators of cancer virotherapy

First-in-class small molecule potentiators of cancer virotherapy | Immunology and Biotherapies | Scoop.it
The use of engineered viral strains such as gene therapy vectors and oncolytic viruses (OV) to selectively destroy cancer cells is poised to make a major impact in the clinic and revolutionize cancer therapy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells

A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells | Immunology and Biotherapies | Scoop.it
Regulatory T cells (Treg) are important for immune homeostasis and are considered of great interest for immunotherapy. The paucity of Treg numbers requires the need for ex vivo expansion.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J. Hematol. Oncol.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J. Hematol. Oncol. | Immunology and Biotherapies | Scoop.it

Journal of Hematology & Oncology 


Abstract 


Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in some patients with advanced melanoma, non-small cell lung cancer (NSCLC), and other tumor types. About 20 % of advanced NSCLC patients and 30 % of advanced melanoma patients experience tumor responses from checkpoint blockade monotherapy, with better clinical responses seen with the combination of anti-PD-1 and anti-CTLA-4 antibodies. Given the power of these new therapies, it is important to understand the complex and dynamic nature of host immune responses and the regulation of additional molecules in the tumor microenvironment and normal organs in response to the checkpoint blockade therapies. In this era of precision oncology, there remains a largely unmet need to identify the patients who are most likely to benefit from immunotherapy, to optimize the monitoring assays for tumor-specific immune responses, to develop strategies to improve clinical efficacy, and to identify biomarkers so that immune-related adverse events can be avoided. At this time, PD-L1 immunohistochemistry (IHC) staining using 22C3 antibody is the only FDA-approved companion diagnostic for patients with NSCLC-treated pembrolizumab, but more are expected to come to market. We here summarize the current knowledge, clinical efficacy, potential immune biomarkers, and associated assays for immune checkpoint blockade therapies in advanced solid tumors. 


KEYWORDS: Biomarker; Cancer immunotherapy; Cytotoxic T cells; Immune checkpoint blockade antibodies; Immune-related adverse events; PD-1; PD-L1; Precision oncology


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, May 29, 7:54 AM
J Hematol Oncol. 2016 May 27;9(1):47. 
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Ma W1,2, Gilligan BM1, Yuan J3,4, Li T5,6.
Krishan Maggon 's curator insight, May 29, 7:57 AM
J Hematol Oncol. 2016 May 27;9(1):47. 
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Ma W1,2, Gilligan BM1, Yuan J3,4, Li T5,6.
Scooped by Gilbert C FAURE
Scoop.it!

CGT to test scaffold tech for commercial-scale T-cell production

CGT to test scaffold tech for commercial-scale T-cell production | Immunology and Biotherapies | Scoop.it
The UK Cell and Gene Therapy Catapult (CGT) will test a “scaffold” technology its Australian developers say could make T-cell production more efficient.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Big Data Sharing Key to Saving Cancer Patients | Articles | ClinicalOMICs

Big Data Sharing Key to Saving Cancer Patients | Articles | ClinicalOMICs | Immunology and Biotherapies | Scoop.it
Sharing of genetic information from millions of cancer patients around the world could be key to revolutionizing cancer prevention and care. Read more at www.ClinicalOMICS.com.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Spatiotemporal Regulation of Hsp90–Ligand Complex Leads to Immune Activation | Immunotherapies and Vaccines

Frontiers | Spatiotemporal Regulation of Hsp90–Ligand Complex Leads to Immune Activation | Immunotherapies and Vaccines | Immunology and Biotherapies | Scoop.it
Hsp90 is the most abundant cytosolic HSP and is known to act as a molecular chaperone.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.

Related Articles
Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.
Toxicol Pathol.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

FDA approves First ever antibody to target Cancer PD-L1

FDA approves First ever antibody to target Cancer PD-L1 | Immunology and Biotherapies | Scoop.it
The European Biotech News Website
Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR models: next-generation CAR modifications for enhanced T-cell function

CAR models: next-generation CAR modifications for enhanced T-cell function | Immunology and Biotherapies | Scoop.it
MTO is an international, online-only, open-access journal focusing on the development and clinical testing of molecular therapies targeting cancer
more...
Krishan Maggon 's curator insight, May 19, 3:28 PM
Molecular Therapy — Oncolytics 3, Article number: 16014 (2016) ​doi:10.1038/mto.2016.14

Daniel Abate-Daga & Marco L Davila
Scooped by Gilbert C FAURE
Scoop.it!

Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis

Rapid and improved characterization of therapeutic antibodies and antibody related products using IdeS digestion and subunit analysis | Immunology and Biotherapies | Scoop.it
Analyst, 2016, Advance Article DOI: 10.1039/C6AN00071A, MinireviewJonathan Sjogren, Fredrik Olsson, Alain Beck Antibody subunits LC, Fd and Fc/2, generated by IdeS digestion has been applied in analytical methodologies to characterize antibody...
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

CAR T Cell Therapy: A Game Changer in Cancer Treatment

CAR T Cell Therapy: A Game Changer in Cancer Treatment | Immunology and Biotherapies | Scoop.it
The development of novel targeted therapies with acceptable safety profiles is critical to successful cancer outcomes with better survival rates. Immunotherapy offers promising opportunities with the potential to induce sustained remissions in patients with refractory disease. Recent dramatic clinical responses in trials with gene modified T cells expressing chimeric antigen receptors (CARs) in B-cell malignancies have generated great enthusiasm. This therapy might pave the way for a potential paradigm shift in the way we treat refractory or relapsed cancers. CARs are genetically engineered receptors that combine the specific binding domains from a tumor targeting antibody with T cell signaling domains to allow specifically targeted antibody redirected T cell activation. Despite current successes in hematological cancers, we are only in the beginning of exploring the powerful potential of CAR redirected T cells in the control and elimination of resistant, metastatic, or recurrent nonhematological cancers. This review discusses the application of the CAR T cell therapy, its challenges, and strategies for successful clinical and commercial translation.
Via Krishan Maggon
Gilbert C FAURE's insight:
scFv suite
more...
Krishan Maggon 's curator insight, May 19, 11:13 AM
Journal of Immunology Research Volume 2016 (2016), Article ID 5474602, 10 pages 

Hilde Almåsbak,1 Tanja Aarvak,1 and Mohan C. Vemuri2 
1Cellular Medicine, Bioproduction, Thermo Fisher Scientific, 0309 Oslo, Norway 2Cell Biology, Thermo Fisher Scientific, Frederick, MD 21704, USA
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Home - GaBI Online - Generics and Biosimilars Initiative

Home - GaBI Online - Generics and Biosimilars Initiative | Immunology and Biotherapies | Scoop.it
Generics and Biosimilars Initiative

The US Food and Drug Administration (FDA) does not formerly recognize non-biological complex drugs (NBCDs), with originators required to follow the new drug application (NDA) route and follow-on NBCDs using the generics – abbreviated new drug application (ANDA) – route [1].

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Clinical development of gene therapy: results and lessons from recent successes

Clinical development of gene therapy: results and lessons from recent successes | Immunology and Biotherapies | Scoop.it
An international, open-access journal publishing top-quality, novel methods and technology development, as well as significant improvements to established techniques in basic, translational, and clinical cell and gene therapy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Recent progress in tracking the viability of transplanted stem cells in vivo

Recent progress in tracking the viability of transplanted stem cells in vivo | Immunology and Biotherapies | Scoop.it
The viability of the transplanted stem cells is particularly crucial in determining the success of stem cell-based regenerative medicine.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells.

Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. | Immunology and Biotherapies | Scoop.it
Related Articles
Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells.
Mol Cancer Ther.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Mammalian target of rapamycin (mTOR) inhibitors in solid tumours

Mammalian target of rapamycin (mTOR) inhibitors in solid tumours | Immunology and Biotherapies | Scoop.it
Abstract
The phosphatidylinositol-3-kinase /protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays an important role in cell proliferation, growth, and angiogenesis.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

EMA Accepts Submission for Rituximab Biosimilar

EMA Accepts Submission for Rituximab Biosimilar | Immunology and Biotherapies | Scoop.it
​Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Medicines Agency has accepted their Marketing Authorization Application for a biosimilar to Roche's EU-licensed MabThera (rituximab).
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study

Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study | Immunology and Biotherapies | Scoop.it
Fardet and colleagues present a large population study assessing the risks of developing infections following glucocorticoid treatment. They describe the impact of age and other conditions such as diabetes on developing infections.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Recent Advances in Immunotherapy for Kidney Cancer

Recent Advances in Immunotherapy for Kidney Cancer | Immunology and Biotherapies | Scoop.it
Abstract: Immunotherapy has been a mainstay of treatment for metastatic renal cell carcinoma (mRCC) since the introduction of high-dose interleukin-2. Recently, improved knowledge of immune regulation and tumor-host immune interactions has led to the development of several novel immunotherapies. Immune checkpoint blockade showed promise in early clinical trials - eventually leading to FDA approval of nivolumab (anti-PD-1) as a second-line treatment for mRCC. Despite encouraging results, PD-1 blockade alone does not achieve durable responses in the majority of patients treated. Improved biomarkers for patient selection, tumor vaccines and combination therapy may augment the efficacy of existing immunotherapies. This review summarizes recent progress in immunotherapy for RCC, focusing on a discussion of emerging agents.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis

Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis | Immunology and Biotherapies | Scoop.it
Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

JHL Biotech opens new biosimilar manufacturing facility in China

JHL Biotech opens new biosimilar manufacturing facility in China | Immunology and Biotherapies | Scoop.it
JHL Biotech (JHL) opened the world’s first KUBio™ biopharmaceutical manufacturing facility with single-use bioprocessing technology at a ribbon-cutting ceremony in Wuhan, China.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Unmasking targets of antitumor immunity via high-throughput antigen profiling

Unmasking targets of antitumor immunity via high-throughput antigen profiling | Immunology and Biotherapies | Scoop.it
Publication date: December 2016 Source:Current Opinion in Biotechnology, Volume 42 Author(s): Sebastiano Battaglia, Jason B Muhitch More than three decades of evidence has established that antitumor immune responses, initially shown with...
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Concise Review: Cellular Therapies: The Potential to Regenerate and Restore Tolerance in Immune-Mediated Intestinal Diseases

Concise Review: Cellular Therapies: The Potential to Regenerate and Restore Tolerance in Immune-Mediated Intestinal Diseases | Immunology and Biotherapies | Scoop.it
Chronic inflammatory enteropathies, including celiac disease, Crohn's disease, and ulcerative colitis, are lifelong disabling conditions whose cure is still an unmet need, despite the great strides made in understanding their complex pathogenesis.
more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

Understanding Jimmy Carter’s Surprise Cancer Turnaround: A Conversation with Jedd Wolchok

Understanding Jimmy Carter’s Surprise Cancer Turnaround: A Conversation with Jedd Wolchok | Immunology and Biotherapies | Scoop.it
Former President Carter’s recent announcement that he is “cancer free” has generated a lot of media attention. Here, we tackle some of the science behind the story.
Via Krishan Maggon
Gilbert C FAURE's insight:
for laypeople and master students
more...
No comment yet.